This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Written informed consent must be signed before implementing any enrollment-related procedures;
Age ≥18 years old;
Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)；
There is no special restriction on the source of genetic test report.
Received surgical treatment for lung tumors.
Received neoadjuvant chemotherapy or radiotherapy.
Received cellular therapy within the last 1 year.
Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases.
A total of 60 patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC would be enrolled from Jiangsu Cancer Institute \& Hospital. In resectable group, we would enroll 20 early-stage cases and 20 operable patients for neoadjuvant treatment . In non-resectable group, 20 advanced-stage inoperable patients would be enrolled.
Cohort
Prospective
Operable
Procedure/SurgeryEnrolled patients capable of surgical treatment
To evaluate the Progression-free Survival (PFS)
Progression-free survival (PFS) is defined as the time from the start of treatment to the occurrence of tumor progression or death due to any cause based on RECIST 1.1 assessed by investigator review.
To evaluate the Overall Survival (OS)
Overall Survival (OS) was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up and the participants who were alive at the date of data cutoff was censored at the date the participant was last known alive, whichever came earlier.
Click on the lead sponsor to view all of their trials.
